Kowa Co Drug Patent Portfolio

Kowa Co owns 1 orange book drug protected by 9 US patents Given below is the list of Kowa Co's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7022713 Hyperlipemia therapeutic agent 19 Aug, 2024 Expired
US8557993 Crystalline forms of pitavastatin calcium 02 Aug, 2024 Expired
US7022713 Hyperlipemia therapeutic agent 19 Feb, 2024 Expired
US8557993 Crystalline forms of pitavastatin calcium 02 Feb, 2024 Expired
US5856336 Quinoline type mevalonolactones 25 Jun, 2021 Expired
US5856336 Quinoline type mevalonolactones 01 Jan, 2021 Expired
US6465477 Stable pharmaceutical composition 20 Dec, 2016 Expired
US5854259 Quinoline type mevalonolactones 29 Dec, 2015 Expired
US5753675 Quinoline analogs of mevalonolactone and derivatives thereof 19 May, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Kowa Co.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 31 Mar, 2021 US8557993 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 21 Sep, 2017 US7022713
Patent Issue Date Used in PTA Calculation 15 Oct, 2013 US8557993 (Litigated)
Recordation of Patent Grant Mailed 15 Oct, 2013 US8557993 (Litigated)
Email Notification 26 Sep, 2013 US8557993 (Litigated)
Issue Notification Mailed 25 Sep, 2013 US8557993 (Litigated)
Dispatch to FDC 20 Sep, 2013 US8557993 (Litigated)
Application Is Considered Ready for Issue 30 Aug, 2013 US8557993 (Litigated)
Issue Fee Payment Verified 28 Aug, 2013 US8557993 (Litigated)
Issue Fee Payment Received 28 Aug, 2013 US8557993 (Litigated)
Electronic Review 21 Aug, 2013 US8557993 (Litigated)
Mail Notice of Allowance 21 Aug, 2013 US8557993 (Litigated)
Email Notification 21 Aug, 2013 US8557993 (Litigated)
Case Docketed to Examiner in GAU 15 Aug, 2013 US8557993 (Litigated)
Notice of Allowance Data Verification Completed 15 Aug, 2013 US8557993 (Litigated)


Kowa Co's Drug Patent Litigations

Kowa Co's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 18, 2015, against patent number US5856336. The petitioner Mylan Pharmaceuticals Inc., challenged the validity of this patent, with Nissan Chemical Industries, Ltd. as the respondent. Click below to track the latest information on how companies are challenging Kowa Co's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US5856336 July, 2015 Terminated-Denied
(04 Feb, 2016)
Nissan Chemical Industries Ltd. Sawai USA, Inc.
US5856336 April, 2015 Terminated-Denied
(20 Oct, 2015)
Nissan Chemical Industries, Ltd. Mylan Pharmaceuticals Inc.


Kowa Co's Family Patents

Kowa Co drugs have patent protection in a total of 17 countries. It's US patent count contributes only to 26.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Kowa Co Drug List

Given below is the complete list of Kowa Co's drugs and the patents protecting them.


1. Livalo

Livalo is protected by 9 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7022713
(Pediatric)
Hyperlipemia therapeutic agent 19 Aug, 2024
(3 months ago)
Expired
US8557993
(Pediatric)
Crystalline forms of pitavastatin calcium 02 Aug, 2024
(3 months ago)
Expired
US7022713 Hyperlipemia therapeutic agent 19 Feb, 2024
(9 months ago)
Expired
US8557993 Crystalline forms of pitavastatin calcium 02 Feb, 2024
(9 months ago)
Expired
US5856336
(Pediatric)
Quinoline type mevalonolactones 25 Jun, 2021
(3 years ago)
Expired
US5856336 Quinoline type mevalonolactones 01 Jan, 2021
(3 years ago)
Expired
US6465477 Stable pharmaceutical composition 20 Dec, 2016
(7 years ago)
Expired
US5854259 Quinoline type mevalonolactones 29 Dec, 2015
(8 years ago)
Expired
US5753675 Quinoline analogs of mevalonolactone and derivatives thereof 19 May, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Livalo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List